At a glance
ClinicalIndex Comparison RecordN/ACompleted· 240 enrolled
Drug / intervention
Synergy +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized COmparison of LoNg-Term Vascular HealiNg bEtween Biodegradable -Polymer (BP) Versus Durable Polymer (DP) Everolimus Eluting Stents in Acute ST-Elevation Myocardial InfarCTion
In Brief
A clinical study evaluating Synergy and Xience for STEMI - ST Elevation Myocardial Infarction. Completed, enrolled 240 participants across 1 site.
Detailed Summary
This study aims to compare the acute thrombogenecity and frequency of neoatherosclerotic lesions and other aspects of long term arterial healing such as the frequency of malapposed and uncovered stent struts at 3 years among patients treated with either a biodegradable polymer everolimus-eluting stent (Synergy) or a durable polymer everolimus-eluting stent (Xience Alpine) for STEMI.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
CollaboratorsInsel Gruppe AG, University Hospital Bern
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedFeb 2018
Primary CompletionJul 2024
Study CompletionSep 2024
TodayJul 2026
First PostedFeb 22, 2018
Enrollment StartJul 3, 2017
Primary CompletionJul 30, 2024
Study CompletionSep 1, 2024
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 8.4 years ago
Interventions
Synergydevice
Biodegradable-polymer everolimus-eluting stent Synergy
Xiencedevice
Durable-polymer everolimus-eluting stent Xience